Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1054 participants.

Also called NCT01001962

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,054 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01001962
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01001962. Randomized; triple masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Acronym
PREHYPD
Condition
Hypertension
Condition
Type II Diabetes
Intervention (Drug)
empagliflozin
Intervention (Drug)
Metformin
Lead sponsor
Aristotle University Of Thessaloniki (class: other)

Record details

Record id
cardio:ct-nct01001962
Content hash
7de8025840aeabaf0206c88cdf9715969c0885ee256a04e2b4d53ef2fd80d7ce